Niki Karavitaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4643740/publications.pdf

Version: 2024-02-01

| | | 81743 | 5 | 56606 |
|----------|-----------------|--------------|---|----------------|
| 106 | 7,368 citations | 39 | | 83 |
| papers | citations | h-index | | g-index |
| | | | | |
| | | | | |
| 162 | 162 | 162 | | 5393 |
| all docs | docs citations | times ranked | | citing authors |
| | | | | |

| # | Article | IF | CITATIONS |
|----|---|-----------|---------------------------|
| 1 | Prevalence of pituitary adenomas: a communityâ€based, crossâ€sectional study in Banbury (Oxfordshire,) Tj ETQq | 112 0.784 | 314 rgBT <mark> </mark> 0 |
| 2 | Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3888-3921. | 1.8 | 601 |
| 3 | Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clinical Endocrinology, 2005, 62, 397-409. | 1.2 | 540 |
| 4 | Craniopharyngiomas. Endocrine Reviews, 2006, 27, 371-397. | 8.9 | 460 |
| 5 | Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875. | 5.5 | 315 |
| 6 | From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer, 2017, 24, C5-C8. | 1.6 | 262 |
| 7 | Epidemiology of acromegaly: review of population studies. Pituitary, 2017, 20, 4-9. | 1.6 | 229 |
| 8 | Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clinical Endocrinology, 2006, 65, 524-529. | 1.2 | 195 |
| 9 | Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4146-4154. | 1.8 | 176 |
| 10 | What is the natural history of nonoperated nonfunctioning pituitary adenomas?. Clinical Endocrinology, 2007, 67, 938-943. | 1.2 | 157 |
| 11 | Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes and Endocrinology, the, 2016, 4, 569-576. | 5.5 | 151 |
| 12 | THERAPY IN ENDOCRINE DISEASE: Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. European Journal of Endocrinology, 2012, 167, 137-143. | 1.9 | 144 |
| 13 | Pheochromocytoma Is Characterized byÂCatecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, andÂMyocardial Dysfunction. Journal of the American College of Cardiology, 2016, 67, 2364-2374. | 1.2 | 139 |
| 14 | Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. European Journal of Endocrinology, 2013, 169, 715-723. | 1.9 | 119 |
| 15 | GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clinical Endocrinology, 2006, 64, 556-560. | 1.2 | 108 |
| 16 | The cortisol stress response induced by surgery: A systematic review and metaâ€analysis. Clinical Endocrinology, 2018, 89, 554-567. | 1.2 | 107 |
| 17 | BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathologica, 2014, 127, 927-929. | 3.9 | 102 |
| 18 | MANAGEMENT OF ENDOCRINE DISEASE: Pituitary tumour apoplexy. European Journal of Endocrinology, 2015, 172, R179-R190. | 1.9 | 102 |

| # | Article | IF | Citations |
|----|--|-----|-----------|
| 19 | Nelson's syndrome. European Journal of Endocrinology, 2010, 163, 495-507. | 1.9 | 94 |
| 20 | Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clinical Endocrinology, 2008, 68, 970-975. | 1.2 | 91 |
| 21 | Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?. European Journal of Endocrinology, 2011, 165, 739-744. | 1.9 | 91 |
| 22 | Craniopharyngiomas. Endocrinology and Metabolism Clinics of North America, 2008, 37, 173-193. | 1.2 | 83 |
| 23 | Diabetes Insipidus after Traumatic Brain Injury. Journal of Clinical Medicine, 2015, 4, 1448-1462. | 1.0 | 79 |
| 24 | Radiation-induced hypopituitarism. Endocrine-Related Cancer, 2009, 16, 733-772. | 1.6 | 72 |
| 25 | Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1889-1897. | 1.8 | 68 |
| 26 | Prevention of Adrenal Crisis: Cortisol Responses to Major Stress Compared to Stress Dose Hydrocortisone Delivery. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2262-2274. | 1.8 | 68 |
| 27 | Hyperprolactinaemia. Journal of Clinical Medicine, 2019, 8, 2203. | 1.0 | 66 |
| 28 | Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1020-1029. | 1.8 | 66 |
| 29 | Collision lesions of the sella: co-existence of craniopharyngioma with gonadotroph adenoma and of Rathke's cleft cyst with corticotroph adenoma. Pituitary, 2008, 11, 317-323. | 1.6 | 65 |
| 30 | THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. European Journal of Endocrinology, 2016, 175, R89-R96. | 1.9 | 63 |
| 31 | Opioid induced hypogonadism. BMJ: British Medical Journal, 2010, 341, c4462-c4462. | 2.4 | 61 |
| 32 | The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical Endocrinology, 2005, 62, 282-288. | 1.2 | 54 |
| 33 | Rathke's cleft cyst. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, 255-269. | 1.0 | 52 |
| 34 | Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. European Journal of Endocrinology, 2016, 174, 137-145. | 1.9 | 51 |
| 35 | Prevalence and incidence of pituitary adenomas. Annales D'Endocrinologie, 2012, 73, 79-80. | 0.6 | 49 |
| 36 | Management of craniopharyngiomas. Journal of Endocrinological Investigation, 2014, 37, 219-228. | 1.8 | 48 |

3

| # | Article | IF | Citations |
|----|---|--------------|-----------|
| 37 | GH replacement in patients with nonâ€functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clinical Endocrinology, 2009, 70, 435-438. | 1.2 | 47 |
| 38 | Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine, 2016, 51, 205-210. | 1.1 | 46 |
| 39 | MECHANISMS OF ENDOCRINOLOGY: Endocrinology of opioids. European Journal of Endocrinology, 2018, 179, R183-R196. | 1.9 | 46 |
| 40 | Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. European Journal of Endocrinology, 2014, 171, K1-K5. | 1.9 | 45 |
| 41 | Epidemiology and mortality of Cushing's syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101521. | 2.2 | 45 |
| 42 | Dopamine agonist resistant prolactinomas: any alternative medical treatment?. Pituitary, 2020, 23, 27-37. | 1.6 | 44 |
| 43 | Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52. | 1.9 | 42 |
| 44 | Opioid-induced endocrinopathies. Lancet Diabetes and Endocrinology, the, 2020, 8, 68-80. | 5 . 5 | 38 |
| 45 | The epidemiology of aggressive pituitary tumors (and its challenges). Reviews in Endocrine and Metabolic Disorders, 2020, 21, 209-212. | 2.6 | 38 |
| 46 | Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ, The, 2014, 349, g5390-g5390. | 3.0 | 35 |
| 47 | Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary, 2020, 23, 322-325. | 1.6 | 34 |
| 48 | Nonfunctioning pituitary adenomas: the Oxford experience. Nature Reviews Endocrinology, 2009, 5, 519-522. | 4.3 | 32 |
| 49 | Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2018, , . | 1.8 | 32 |
| 50 | Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16. | 1.9 | 32 |
| 51 | Non-adenomatous pituitary tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 651-665. | 2.2 | 31 |
| 52 | Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, byaa205. | 0.1 | 31 |
| 53 | Endocrinology in the time of COVID-19: Management of pituitary tumours. European Journal of Endocrinology, 2020, 183, G17-G23. | 1.9 | 31 |
| 54 | Mortality in patients with non-functioning pituitary adenoma. Pituitary, 2018, 21, 203-207. | 1.6 | 30 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The Wnt Signalling Cascade and the Adherens Junction Complex in Craniopharyngioma Tumorigenesis. Endocrine Pathology, 2015, 26, 1-8. | 5.2 | 29 |
| 56 | Silent corticotroph adenomas. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1314-1318. | 1.3 | 28 |
| 57 | Efficacy and Complications of Pituitary Irradiation. Endocrinology and Metabolism Clinics of North America, 2015, 44, 117-126. | 1.2 | 28 |
| 58 | A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4189-4194. | 1.8 | 27 |
| 59 | The Medical Therapy of Craniopharyngiomas: The Way Ahead. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5751-5764. | 1.8 | 26 |
| 60 | Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1527-1537. | 1.8 | 26 |
| 61 | The diagnosis and management of Cushing's syndrome in pregnancy. Journal of Neuroendocrinology, 2022, 34, e13118. | 1.2 | 25 |
| 62 | Association of prolactin receptor (<i>PRLR</i>) variants with prolactinomas. Human Molecular Genetics, 2019, 28, 1023-1037. | 1.4 | 24 |
| 63 | Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society―survey. Pituitary, 2019, 22, 37-45. | 1.6 | 24 |
| 64 | Recent advances in molecular pathology of craniopharyngioma. F1000Research, 2017, 6, 1202. | 0.8 | 22 |
| 65 | Males with prolactinoma are at increased risk of incident cardiovascular disease. Clinical Endocrinology, 2018, 88, 71-76. | 1.2 | 22 |
| 66 | Pituitary disorders in pregnancy. Hormones, 2015, 14, 70-80. | 0.9 | 21 |
| 67 | Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?. Clinical Endocrinology, 2013, 79, 217-223. | 1.2 | 20 |
| 68 | Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes. Clinical Endocrinology, 2017, 87, 508-514. | 1.2 | 20 |
| 69 | Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clinical Endocrinology, 2018, 89, 346-353. | 1.2 | 20 |
| 70 | MANAGEMENT OF ENDOCRINE DISEASE: Visual morbidity in patients with pituitary adenoma. European Journal of Endocrinology, 2019, 181, R185-R197. | 1.9 | 20 |
| 71 | Clinical and biochemical manifestations of Cushing's. Pituitary, 2015, 18, 181-187. | 1.6 | 19 |
| 72 | Pituitary metastases: presentation and outcomes from a pituitary center over the last decade. Pituitary, 2020, 23, 258-265. | 1.6 | 17 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Cushing's syndrome update: 100 years after Minnie G. Journal of Neuroendocrinology, 2022, 34, . | 1.2 | 17 |
| 74 | The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clinical Endocrinology, 2009, 71, 840-845. | 1.2 | 15 |
| 75 | Adrenal insufficiency in acute oral opiate therapy. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 130071. | 0.2 | 15 |
| 76 | Incidence, risk factors and clinical significance of postoperative haemodynamic instability after adrenalectomy for phaeochromocytoma. Gland Surgery, 2019, 8, 729-739. | 0.5 | 15 |
| 77 | Opioids and pituitary function: expert opinion. Pituitary, 2022, 25, 52-63. | 1.6 | 15 |
| 78 | Neurofibromatosis Type 1 and pancreatic islet cell tumours: an association which should be recognized. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 573-576. | 0.2 | 14 |
| 79 | Nelson's Syndrome. Endocrinology and Metabolism Clinics of North America, 2020, 49, 413-432. | 1.2 | 14 |
| 80 | Craniopharyngiomas. Historical aspects of their management. Hormones, 2008, 7, 271-274. | 0.9 | 13 |
| 81 | Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. European Journal of Endocrinology, 2014, 171, 705-710. | 1.9 | 12 |
| 82 | Mortality of Patients with Cushing's Disease. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 203-207. | 0.6 | 11 |
| 83 | A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, . | 0.2 | 9 |
| 84 | Bilateral adrenal haemorrhage. QJM - Monthly Journal of the Association of Physicians, 2017, 110, hcw212. | 0.2 | 7 |
| 85 | Histopathology of Parasellar Neoplasms. Neuroendocrinology, 2020, 110, 740-752. | 1.2 | 6 |
| 86 | Cushing's Disease – Quality of Life, Recurrence and Long-term Morbidity. European Endocrinology, 2015, 11, 34. | 0.8 | 6 |
| 87 | Radiotherapy of other sellar lesions. Pituitary, 2009, 12, 23-29. | 1.6 | 5 |
| 88 | A rare challenging case of co-existent craniopharyngioma, acromegaly and squamous cell lung cancer. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, . | 0.2 | 5 |
| 89 | Craniopharyngiomas. Presse Medicale, 2021, 50, 104078. | 0.8 | 5 |
| 90 | Non-functioning pituitary adenomas, not all the same and certainly not boring!. Pituitary, 2018, 21, 109-110. | 1.6 | 4 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Hypopituitarism Oddities: Craniopharyngiomas. Hormone Research in Paediatrics, 2007, 68, 151-153. | 0.8 | 3 |
| 92 | Diagnosis of pituitary disease. Medicine, 2017, 45, 464-469. | 0.2 | 3 |
| 93 | Recent advances in the management of acromegaly. F1000Research, 2015, 4, 1426. | 0.8 | 3 |
| 94 | Pegvisomant: a new treatment modality for acromegaly. Hormones, 2004, 3, 27-36. | 0.9 | 3 |
| 95 | Metastatic colon cancer in the pituitary: A case report with review of literature. Journal of Innovative Optical Health Sciences, 2021, 16, 872-875. | 0.5 | 3 |
| 96 | Postradioiodine Graves' management: The PRAGMA study. Clinical Endocrinology, 2022, 97, 664-675. | 1.2 | 3 |
| 97 | A Patient with an Apparently Sporadic Pheochromocytoma with a Rearranged During Transfection Codon 635 Variant: A Mild Form of Multiple Endocrine Neoplasia Type 2?. Endocrine Practice, 2014, 20, e65-e68. | 1.1 | 2 |
| 98 | Perioperative endocrinological management in patients with pituitary adenomas., 2021,, 421-427. | | 2 |
| 99 | Response to Letter to the Editor: "Prevention of Adrenal Crisis: Cortisol Response to Major Stress Compared to Stress Dose Hydrocortisone Delivery― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e404-e406. | 1.8 | 1 |
| 100 | Clinical Diagnosis of Human ACP., 2017, , 57-66. | | 1 |
| 101 | Hypopituitarism, Causes, Diagnosis, Management and Mortality. , 2018, , 301-313. | | O |
| 102 | Macroprolactinoma causing VI, X, XII cranial nerve palsies nearly 30 years after initial treatment. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, . | 0.2 | 0 |
| 103 | Response to Letter to the Editor from Chee et al: "Prevention of Adrenal Crisis: Cortisol Response to Major Stress Compared to Stress Dose Hydrocortisone Delivery― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e407-e408. | 1.8 | 0 |
| 104 | Pituitary Disorders: Striving for Excellence. Endocrinology and Metabolism Clinics of North America, 2020, 49, xvii-xviii. | 1.2 | 0 |
| 105 | Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , . | 1.8 | 0 |
| 106 | Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , . | 1.8 | 0 |